SANDS ARTHUR T 4
4 · Nurix Therapeutics, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) CEO Arthur T. Sands Receives 562,500-Share Option Award
What Happened Arthur T. Sands (President, CEO and Director) received a derivative equity award of 562,500 shares on February 10, 2026. The filing reports the transaction price as $0.00 (i.e., a grant/award of a derivative instrument rather than a cash purchase or sale). No cash was paid and no shares were sold in this filing.
Key Details
- Transaction date: 2026-02-10; transaction type: Grant/Award (code A).
- Amount: 562,500 derivative shares; reported price: $0.00.
- Shares owned after transaction: Not specified in the provided filing.
- Footnote: The option vests 1/36 of the total shares monthly beginning March 10, 2026, and fully vests on February 9, 2029, subject to continued service.
- Filing timeliness: Reported and filed on 2026-02-10; no late filing indicated.
- No 10b5-1 plan, tax-withholding sale, or immediate exercise/sale reported.
Context This is a time-based equity grant (typical executive compensation) that vests over three years; it is not an immediate purchase or sale and does not create freely tradable shares until vesting/exercise. Such grants align executive incentives with company performance and retention but do not by themselves indicate insider buying or selling sentiment.
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1]2026-02-10+562,500→ 562,500 totalExercise: $16.45Exp: 2036-02-09→ Common Stock (562,500 underlying)
Footnotes (1)
- [F1]The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.